◆ TICKERBASE · US STOCK FINANCIAL DATA LIBRARY

HomeAll stocks › YDES

YD Bio Ltd (YDES) Financial History

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Biotechnology · DATA UPDATED 2026-07-10

YD Bio Ltd (YDES) operates in the Biotechnology industry and is headquartered in Taipei, Taiwan. Its market capitalization is roughly $152 million. In the fiscal year ended 2025-12-31, YDES reported $1M in revenue and ($8M) in net income.

YD Bio Limited a biopharmaceutical company focuses on blood-based cancer detection and develops stem cell- and exosome-based therapeutics to transform the treatment of spectrum of diseases with unmet medical needs. The company is based in Taipei, Taiwan.

Interactive charts & full statements → Open the YDES valuation workbench →

YDES Revenue & Earnings History — Annual Income Statement

Income statement2025-12-312024-12-312023-12-31
Total Revenue$1M$0M$0M
Gross Profit$0M$0M$0M
Operating Income (EBIT)($5M)($2M)$0M
Net Income($8M)($1M)$0M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

YDES Free Cash Flow History

YDES Balance Sheet History

Balance sheet2025-12-312024-12-312023-12-31
Total Assets$14M$7M$0M
Total Liabilities$17M$0M$0M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive YDES viewer.

Other Companies in Biotechnology

← YDDLAll stocksYDKG →

About TickerBase · Data methodology & sources

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.